放疗联合雄激素剥夺治疗对基线性功能良好局限性前列腺癌患者性功能结局的影响
本研究回顾性分析了前瞻性人群队列中167例基线勃起功能足以完成性交的局限性前列腺癌患者,比较放疗联合或不联合雄激素剥夺治疗(ADT)后5年内的性功能变化。结果显示,ADT联合放疗在治疗1年内与更差的性功能相关,且在高危患者中该差异持续至3年,但在5年时不再显著;中危患者中联合ADT在3年及5年随访时未显示更差的性功能。
要点
- 高危前列腺癌患者放疗联合ADT在3年随访时性功能显著差于单纯放疗。
- 中危患者联合ADT在3年及5年随访时性功能与单纯放疗无显著差异。
- ADT使用在1年内与更差性功能相关, regardless of disease risk。
核心结论
- 高危前列腺癌患者接受放疗联合ADT在3年随访时性功能差于单纯放疗,但5年时差异不显著。
- 中危患者联合ADT在3年或5年随访时未显示比单纯放疗更差的性功能。
研究设计与样本
- 回顾性分析前瞻性人群队列,纳入167例基线勃起功能足以完成性交的局限性前列腺癌患者。
- 73例接受单纯放疗,94例接受ADT联合放疗(中危51例,高危43例),纵向评估性功能至5年。
主要发现
- ADT使用在1年内与更差性功能相关,无论疾病风险如何。
- 中危组中该差异在3年时不再有统计学显著性。
- 高危组中ADT联合放疗相比单纯放疗在3年时性功能更差(效应值-20.3分,CI [-31.8, -8.8],p < 0.001),5年时无显著差异(效应值-3.4,CI [-17.2, 10.5],p = 0.63)。
临床怎么用
- 对基线性功能良好的高危前列腺癌患者,考虑ADT联合放疗时应告知3年内性功能可能更差的风险。
- 中危患者联合ADT对3至5年性功能的影响与单纯放疗无显著差异,可据此进行个体化决策。
局限性
- 回顾性研究设计。
- 样本量有限(167例),尤其高危组43例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sexual dysfunction, including erectile dysfunction and loss of libido, are common among men undergoing treatment for localized prostate cancer. Both local treatments and systemic androgen deprivation therapy may contribute to these outcomes and are differentially indicated based on disease characteristics. We sought to compare sexual function through 5 years after radiation treatment with and without androgen deprivation therapy in men with good baseline sexual function to better understand long-term effects in this understudied subset of patients. METHODS: We retrospectively reviewed a prospectively assembled population-based cohort of men who underwent radiation with and without androgen deprivation therapy for intermediate or high-risk localized prostate cancer. Sexual function was assessed longitudinally over 5 years. Men with erections sufficient for intercourse at baseline were selected for inclusion. RESULTS: Out of 167 patients included, 73 underwent radiation alone and 94 received androgen deprivation therapy plus radiation (51 with intermediate and 43 with high-risk disease). Androgen deprivation therapy use was associated with worse sexual function through 1 year regardless of disease risk. This difference was no longer statistically significant at 3 years in the intermediate-risk group. Compared to radiation alone, androgen deprivation therapy in high-risk disease was associated with worse sexual function at 3 years (effect: -20.3 points, CI [-31.8, -8.8], p < 0.001) but not at 5 years (effect: -3.4, CI [-17.2, 10.5], p = 0.63). CONCLUSIONS: Androgen deprivation therapy plus radiation is associated with worse sexual function through 3-years follow-up in men with high-risk prostate cancer compared to radiation alone. The addition of androgen deprivation therapy in the treatment of intermediate-risk disease does not appear to result in worse sexual function at 3 or 5-year follow-up compared to radiation alone.
引用
- Joyce DD, Wallis CJD, Luckenbaugh AN, et al. Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function. Prostate Cancer Prostatic Dis. 2021. PMID: 34108648. doi:10.1038/s41391-021-00405-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。